GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • The FDA review highlights several safety issues with flibanserin, including low blood pressure and fainting spells. A panel of FDA experts will discuss the drug at a public meeting Thursday, before voting on whether to recommend its approval. Supporters of Sprout's drug say women's sexual disorders have been long overlooked by the FDA.

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • Pfizer gaining market share in oncology: CEO Monday, 1 Jun 2015 | 1:09 PM ET
    Ian Read, CEO of Pfizer.

    Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.

  • Merck's fight against cancer   Monday, 1 Jun 2015 | 1:08 PM ET
    Merck's fight against cancer

    Merck's executive vice president Dr. Roger Perlmutter, discusses research on immunotherapy for certain colon cancers, and the players in the fight against cancer.

  • Biotech isn't only health-care bet beating market Monday, 1 Jun 2015 | 10:09 AM ET
    An employee works on a stent graft component in a sterile environment at the Medtronic assembly plant in Tijuana, Mexico.

    The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.

  • The National Cancer Institute's NCI-MATCH trial will be a massive precision medicine experiment at more than 2,400 sites around the country. Douglas Lowy, the Cancer Institute's acting director. Details of the study were revealed Monday at an American Society of Clinical Oncology conference in Chicago.

  • Could virus make the leap from birds to people? Saturday, 30 May 2015 | 12:02 PM ET
    Lacey Kurth, a research associate, works with avian influenza test samples during testing in the real-time analytical diagnostics lab at the Iowa State University College of Veterinary Medicine in Ames, Iowa.

    There have only been four flu pandemics since the start of the 20th century, yet concerns are widening about the potential for a new outbreak.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • CHICAGO— For the first time, a major study shows that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer. Doctors also may have found a way to help predict which patients would respond best to one of these newer treatments, according to research presented at the Chicago meeting.

  • OPDIVO BENEFIT SIGNIFICANTLY HIGHER IN LUNG CANCER TUMORS WITH HIGH LEVEL OF PD-L1 PROTEIN-STUDY.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...

  • BRISTOL'S OPDIVO CUTS DEATH RISK 27 PCT IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER-STUDY.

  • BRISTOL-MYERS SQUIBB'S OPDIVO EXTENDS SURVIVAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER-STUDY.

  • WASHINGTON, May 28- The U.S. Food and Drug Administration on Thursday approved the first drug to treat a rare, progressive lung disease that mainly affects women of childbearing age. The drug, Rapamune, known chemically as sirolimus, is made by Pfizer Inc and is designed to treat lymphangioleiomyomatosis, a disease that causes lung damage and affects only two to...

  • WASHINGTON, May 28- U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit over the sleep disorder drug Provigil, the Federal Trade Commission said on Thursday. Cephalon had been accused by the FTC of illegally protecting its monopoly on Provigil by...

  • Flaws in gene testing revealed Wednesday, 27 May 2015 | 1:37 PM ET
    Genetic testing

    The first report from a big public-private project to improve genetic testing reveals it is not as rock solid as many people believe.

  • Galena Biopharma rises on cancer therapy study Wednesday, 27 May 2015 | 1:37 PM ET

    NEW YORK— Shares of Galena Biopharma rose Wednesday after the cancer drug developer reported promising data from a clinical study of a second potential cancer vaccine. Galena Biopharma said its drug GALE-301 was well-tolerated and patients' immune systems responded to treatment. Maxim Group analyst Jason McCarthy said GALE-301 is similar to a more...

  • May 27- Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low. GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for...

  • Zogenix says former obesity drug reduced seizures in study Wednesday, 27 May 2015 | 11:54 AM ET

    Zogenix said it plans to start late-stage testing of the drug in the second half of 2015, and it hopes to file for marketing approval in the U.S. and the European Union in late 2016.. Zogenix said research has long shown that it can reduce epileptic seizures, however. It is a component of Vivus Inc.' s anti-obesity drug Qsymia.